Instil Bio Soars 11.3% on New CMO Appointment

On June 3, 2025, Instil Bio's stock rose by 11.3% in pre-market trading, reflecting a significant surge that has garnered attention from investors and analysts.

Instil Bio has recently appointed Jamie Freedman, M.D., Ph.D., as its new Chief Medical Officer. Dr. Freedman's extensive experience in hematology-oncology and his proven track record in drug development and regulatory approvals are expected to bolster the company's leadership and enhance its research capabilities. This strategic move is aimed at advancing the company's lead candidate, AXN-2510, which has shown promising results in clinical trials. Investors are optimistic about the potential impact of Dr. Freedman's expertise on the company's pipeline and future growth prospects.